Ingevity's Q4 2025 was characterized by a significant GAAP net loss of $84.6 million, primarily due to $109.3 million in non-cash impairment charges related to the Road Markings product line. However, the company maintained a strong adjusted EBITDA margin of 27.6% for continuing operations and generated robust free cash flow of $73.5 million, allowing for debt reduction and share repurchases.

Ingevity delivered a resilient third quarter in 2025, with net sales from continuing operations remaining flat at $333.1 million. The company achieved a net income of $43.5 million and diluted EPS of $1.18. Total Adjusted EBITDA increased by 14% to $121.2 million, with the margin improving to 33.5%. Strong operating cash flow of $129.7 million and free cash flow of $117.8 million enabled accelerated deleveraging and share repurchases.

Ingevity's second quarter 2025 results showed a 7% decline in net sales to $365.1 million, primarily due to lower sales in Performance Chemicals. The company reported a net loss of $146.5 million and diluted loss per share of $4.02, largely impacted by a $183.8 million non-cash goodwill impairment charge related to Advanced Polymer Technologies. However, adjusted earnings increased by 39% to $51.1 million, and adjusted EBITDA rose by 9% to $110.0 million, with the adjusted EBITDA margin improving to 30.1%, driven by successful repositioning actions in Performance Chemicals.

Ingevity reported a decrease in net sales for Q1 2025, primarily due to repositioning actions in Performance Chemicals. However, the company saw an increase in adjusted EBITDA and improved adjusted EBITDA margin, driven by successful repositioning and continued strong profitability in Performance Materials. Net income and EPS were positive despite special charges.

Ingevity's fourth quarter of 2024 saw a significant 20% decrease in net sales, primarily driven by strategic repositioning actions in the Performance Chemicals segment, which involved exiting lower-margin end markets. Despite this, the company reported a substantial 91% increase in adjusted EBITDA, reflecting the benefits of these repositioning efforts and a non-cash inventory charge in the prior year. Net income for the quarter was $16.6 million, with diluted EPS of $0.46.

Ingevity reported a 16% decrease in net sales to $376.9 million, primarily due to repositioning actions in Performance Chemicals. The company experienced a net loss of $107.2 million, which includes significant restructuring charges and contract termination fees. However, adjusted earnings were $40.2 million, with an adjusted EPS of $1.10. The company affirms its full-year guidance for sales and adjusted EBITDA.

Ingevity reported a decrease in net sales by 19% to $390.6 million, primarily due to the repositioning of its Performance Chemicals segment. The company experienced a net loss of $283.7 million, or $7.81 per share, due to a $349.1 million non-cash goodwill impairment charge in Performance Chemicals. Adjusted EBITDA decreased by 16% to $101.3 million, with a margin of 25.9%.

Ingevity's first quarter 2024 net sales were $340.1 million, a 13% decrease compared to the prior year, primarily due to the repositioning of the Performance Chemicals segment. The company reported a net loss of $56.0 million, or $1.54 per share, while adjusted earnings were $19.1 million, or $0.52 per share. Adjusted EBITDA was $76.9 million, with a margin of 22.6%.

Ingevity's third quarter net sales decreased by 7% compared to the prior year, with weak industrial demand impacting Advanced Polymer Technologies and Industrial Specialties. Net income and EPS also decreased. However, the company maintained mid-twenties adjusted EBITDA margins due to its specialty businesses and cost reduction actions.

Ingevity Corporation reported a 15% increase in net sales to $481.8 million for the second quarter of 2023. Net income was $35.5 million, with diluted EPS at $0.97. Adjusted EBITDA remained flat at $120.7 million, with a margin of 25.1%. The company has initiated cost reduction actions expected to yield $35 million in annualized savings.

Ingevity's first quarter 2023 results showed a slight increase in net sales, but a decrease in net income and adjusted EBITDA. The company faced challenges including a slow start in China, customer destocking, and rising raw material costs, but saw strong performance in certain segments and regions.

Ingevity reported a 14.2% increase in Q4 net sales to $383.6 million, but net income decreased 47% to $15.6 million due to customer destocking. Despite Q4 challenges, full year 2022 was a record year for net sales and EBITDA.

Ingevity reported record sales of $482.0 million, up 27.9% year-over-year, driven by strong demand and increased prices. Net income was $75.4 million, with diluted EPS of $1.98. Adjusted EBITDA reached a record $138.2 million, up 15.6% year-over-year, with an adjusted EBITDA margin of 28.7%. The company raised its full-year 2022 sales and adjusted EBITDA guidance.

Ingevity reported record sales of $419.9 million, a 17.2% increase year-over-year. The company also announced two strategic growth investments: the acquisition of Ozark Materials and an investment in Nexeon Limited.

Ingevity reported a strong first quarter in 2022, marked by record sales of $382.8 million, a 19.5% increase. Net income rose to $60.8 million, with diluted EPS at $1.55. The company has adjusted its full-year guidance, increasing the top end of the ranges to sales between $1.525 billion and $1.65 billion and adjusted EBITDA between $430 million and $470 million.

Ingevity Corporation reported a 3.2% increase in net sales for Q4 2021, reaching $336.0 million, and a 14.4% increase for the full year, with net sales of $1.4 billion. Despite these gains, net income for Q4 decreased by 36.3% to $29.3 million, while adjusted earnings decreased by 43.9% to $30.9 million, primarily due to the microchip shortage impacting automotive emission product volumes.

Ingevity's third quarter net sales increased by 13.6% year-over-year to $376.8 million. However, the company reported a net loss of $4.2 million, which included a significant pre-tax expense for a litigation verdict. Adjusted earnings were $64.4 million, and adjusted EBITDA was $119.5 million. The company has updated its full-year guidance to sales between $1.320 billion and $1.360 billion and adjusted EBITDA between $405 million and $420 million.

Ingevity reported strong second quarter results with net sales up 32.4% to $358.4 million and net income up 119.3% to $44.3 million. Adjusted EBITDA increased by 75.1% to $117.7 million. The company also increased its full year 2021 guidance for sales and adjusted EBITDA.

Ingevity reported a strong first quarter in 2021, with net sales up 11.1% to $320.3 million and net income up 7.5% to $48.7 million. Adjusted EBITDA increased by 14.3% to $105.4 million. The company has increased its fiscal year 2021 guidance for sales and adjusted EBITDA.

Ingevity reported a 7.3% increase in net sales to $325.6 million and a 14.7% increase in net income to $50.8 million for the fourth quarter of 2020. Strong automotive production and sales in China and a favorable shift to trucks and SUVs in the U.S. and Canada were significant tailwinds. The company's adjusted EBITDA margin rose to a fourth quarter record.

Ingevity reported Q3 2020 net sales of $332 million, a decrease of 7.8% compared to the prior year quarter. Net income increased by 16.7% to $70 million, and adjusted EBITDA rose by 11.9% to $128 million. The company also generated $74 million in free cash flow and increased its full-year adjusted EBITDA guidance to $355 million - $365 million and sales guidance to $1.15 billion - $1.20 billion.

Ingevity's Q2 2020 net sales were $270.6 million, a 23.3% decrease compared to the prior year quarter. Net income was $20.2 million, a 64.4% decrease, with diluted earnings per share at $0.49. The company reaffirmed its fiscal year 2020 guidance for sales and adjusted EBITDA.

Ingevity reported a strong first quarter with net sales up 4.1% and a significant increase in net income and adjusted EBITDA. The company's performance was driven by growth in Performance Materials, although the coronavirus had some impact. Ingevity is revising fiscal year 2020 guidance due to uncertainties related to COVID-19.

Ingevity reported Q4 2019 net sales of $303.4 million, up 8.9% year-over-year, and net income of $44.3 million, up 5.2% year-over-year. Adjusted EBITDA was $91.1 million, up 24.3% year-over-year, with an adjusted EBITDA margin of 30.0%. The company announced FY 2020 guidance of sales between $1.30 billion and $1.35 billion and adjusted EBITDA between $400 million and $420 million.